2025 China Adult And Pediatric Vaccines Market Revenue Opportunities Report
Description
The 2025 China Adult And Pediatric Vaccines Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult and Pediatric Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Adult and Pediatric Vaccines Market in China are Sinopharm Group, Sinovac Biotech, Walvax Biotechnology, and Chongqing Zhifei Biological Products. Sinopharm Group, China’s leading vaccine maker, has extensive domestic vaccine production and distribution capabilities. Sinovac Biotech is notable for its COVID-19 vaccines and broad immunization portfolio. Walvax Biotechnology has developed pediatric vaccines such as the 13-valent Pneumococcal Conjugate Vaccine (PCV13), showing strong clinical trial results in Chinese infants. Chongqing Zhifei Biological Products is another major player specializing in vaccines for various age groups in China.
Foreign multinational companies like Merck and GSK have historically been significant players but now face challenges in China due to regulatory scrutiny, price competition from local firms, and changing consumer behaviors. Merck paused sales of its HPV vaccine Gardasil temporarily, and GSK restructured its shingles vaccine distribution to adapt. Meanwhile, domestic firms like Wantai Biopharm and Changchun BCHT Biotechnology have entered with competitive HPV and shingles vaccines, disrupting foreign firms’ pricing models. The market is trending toward domestic companies capturing larger shares through lower prices and high volumes amid China's push for pharmaceutical self-sufficiency.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult and Pediatric Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Adult and Pediatric Vaccines Market in China are Sinopharm Group, Sinovac Biotech, Walvax Biotechnology, and Chongqing Zhifei Biological Products. Sinopharm Group, China’s leading vaccine maker, has extensive domestic vaccine production and distribution capabilities. Sinovac Biotech is notable for its COVID-19 vaccines and broad immunization portfolio. Walvax Biotechnology has developed pediatric vaccines such as the 13-valent Pneumococcal Conjugate Vaccine (PCV13), showing strong clinical trial results in Chinese infants. Chongqing Zhifei Biological Products is another major player specializing in vaccines for various age groups in China.
Foreign multinational companies like Merck and GSK have historically been significant players but now face challenges in China due to regulatory scrutiny, price competition from local firms, and changing consumer behaviors. Merck paused sales of its HPV vaccine Gardasil temporarily, and GSK restructured its shingles vaccine distribution to adapt. Meanwhile, domestic firms like Wantai Biopharm and Changchun BCHT Biotechnology have entered with competitive HPV and shingles vaccines, disrupting foreign firms’ pricing models. The market is trending toward domestic companies capturing larger shares through lower prices and high volumes amid China's push for pharmaceutical self-sufficiency.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
